Sarepta Therapeutics Stock Soars Despite Adverse Event Worries

Sarepta Therapeutics Stock Soars Despite Adverse Event Worries

Late last week, some Sarepta Therapeutics (NASDAQ: SRPT) investors were worried. Now the weekend is over, and all of those worries seem to have dissipated.

Concerns arose after the U.S. Food and Drug Administration (FDA) made its database of prescription drug adverse events easily searchable. Sarepta stock fell on Friday after investors saw troubling adverse event data for the biotech's Duchenne muscular dystrophy (DMD) drug Exondys 51. However, Sarepta's share price jumped 7% on Monday. What happened to ease investors' minds?

Image source: Getty Images.

Continue reading

Source: Fool.com